Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor

Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor

Respiratory syncytial virus causes lung infections in children, immunocompromised adults, and in the elderly. Here the authors show that a chemical inhibitor to a viral fusion protein is effective in reducing viral titre and ameliorating infection in rodents and neonatal lambs.

Bibliographic Details
Main Authors: Dirk Roymans, Sarhad S Alnajjar, Michael B Battles, Panchan Sitthicharoenchai, Polina Furmanova-Hollenstein, Peter Rigaux, Joke Van den Berg, Leen Kwanten, Marcia Van Ginderen, Nick Verheyen, Luc Vranckx, Steffen Jaensch, Eric Arnoult, Richard Voorzaat, Jack M. Gallup, Alejandro Larios-Mora, Marjolein Crabbe, Dymphy Huntjens, Pierre Raboisson, Johannes P. Langedijk, Mark R. Ackermann, Jason S McLellan, Sandrine Vendeville, Anil Koul
Format: Article
Language:English
Published: Nature Publishing Group 2017-08-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-017-00170-x

Internet

https://doi.org/10.1038/s41467-017-00170-x

Similar Items